Literature DB >> 1283100

Structural aspects of the IGFBP family.

S L Drop1, A G Schuller, D J Lindenbergh-Kortleve, C Groffen, A Brinkman, E C Zwarthoff.   

Abstract

To date six IGF binding proteins (IGFBP) have been characterized. Analysis of the amino acid sequence reveals that the IGFBPs are clearly distinct but are sharing regions with strong homology. Specifically the hydrophobic cysteine rich N-terminal region and to a lesser extend the C-terminal part are preserved. The alignment of the cysteine molecules is strongly conserved across the 6 IGFBPs. The middle one-third region, where no cysteines are present (except for IGFBP-4) is most divergent. IGFBP-3 and -4 are glycosylated, whereas IGFBP-1 and -2 contain an Arg-Gly-Asp sequence near the carboxyl terminus. Determination of the number of free-SH groups of IGFBP-1 and -3 has revealed that most likely all cysteine residues are involved in disulfide bond formation. All members of the IGFBP family bind IGF-I and IGF-II with about equal affinity. Studies involving deletion mutation and site-directed mutagenesis of IGFBP-1 and -3 have suggested that the three-dimensional structure of the protein plays an important role in IGF binding. However at present it is unclear whether the IGFBPs share one or more specific IGF binding domain. The predominant function of the IGFBPs is to allocate IGF in the various body fluid compartments and tissues and to modulate IGF binding to receptors. For this purpose there exists a very sophisticated control of the routing of circulating IGF both from and to the cell. There is mounting evidence that the structure of the IGFBP proteins plays a key role in the regulation of IGF bioavailability, by modulating its molecular size, capillary membrane permeability, target tissue specificity, cell membrane adherence and IGF affinity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1283100

Source DB:  PubMed          Journal:  Growth Regul        ISSN: 0956-523X


  7 in total

Review 1.  Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases?

Authors:  Terry J Smith
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

2.  Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid.

Authors:  K Swisshelm; K Ryan; K Tsuchiya; R Sager
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

3.  Elevated levels of IL-6 and IGFBP-1 predict low serum IGF-1 levels during continuous infusion of rhIGF-1/rhIGFBP-3 in extremely preterm infants.

Authors:  Susanna Klevebro; Gunnel Hellgren; Ingrid Hansen-Pupp; Dirk Wackernagel; Boubou Hallberg; Jan Borg; Aldina Pivodic; Lois Smith; David Ley; Ann Hellström
Journal:  Growth Horm IGF Res       Date:  2019-11-09       Impact factor: 2.372

4.  Production of IGF-I and IGF binding proteins by retinal cells in vitro.

Authors:  P Moriarty; M Boulton; A Dickson; D McLeod
Journal:  Br J Ophthalmol       Date:  1994-08       Impact factor: 4.638

5.  Expression of insulin-like growth factors (IGFs), their receptors and IGF binding protein-3 in normal, benign and malignant smooth muscle tissues.

Authors:  L T Van der Ven; P J Roholl; T Gloudemans; S C Van Buul-Offers; M J Welters; B A Bladergroen; J A Faber; J S Sussenbach; W Den Otter
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

6.  Dysregulated IGFBP5 expression causes axon degeneration and motoneuron loss in diabetic neuropathy.

Authors:  Christian M Simon; Stefanie Rauskolb; Jennifer M Gunnersen; Bettina Holtmann; Carsten Drepper; Benjamin Dombert; Massimiliano Braga; Stefan Wiese; Sibylle Jablonka; Dirk Pühringer; Jürgen Zielasek; Andreas Hoeflich; Vincenzo Silani; Eckhard Wolf; Susanne Kneitz; Claudia Sommer; Klaus V Toyka; Michael Sendtner
Journal:  Acta Neuropathol       Date:  2015-05-30       Impact factor: 17.088

7.  Insulin-like growth factor binding proteins increase intracellular calcium levels in two different cell lines.

Authors:  Danielle Seurin; Alain Lombet; Sylvie Babajko; François Godeau; Jean-Marc Ricort
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.